Compensation for healthcare providers rose some 4.3% in 2025. The sobering news is that the gain owes more to heavier daily workloads than to bigger per-patient billings.
Carotid artery disease causes up to 30% of all strokes, but severely calcified lesions can make treatment quite complex. The hope is that IVL can be as successful in this area as it has been in the treatment of coronary and peripheral artery disease.
Targeted interventions could help reduce pre-test anxiety, improve the physical screening experience, and address structural barriers in underserved settings.
The U.S. Department of Justice is appealing a lower court’s ruling that would see 16,000 federal employees return to work, including many from Veterans Affairs.
The subcutaneous drug, sold under the brand name Amvuttra, joins an ATTR-CM market that already includes Pfizer’s tafamidis (Vyndaqel, Vyndamax) and BridgeBio’s acoramidis (Attruby).
Abbott has received an investigational device exemption from the FDA for a new clinical trial evaluating the safety and effectiveness of using its coronary IVL technology. The trial is expected to enroll up to 335 U.S. patients.
Compensation for healthcare providers rose some 4.3% in 2025. The sobering news is that the gain owes more to heavier daily workloads than to bigger per-patient billings.